Amgen’s AMG510 clinical data deemed encouraging for NSCLC on ASCO update with single-agent potential; CRC data disappointing but higher dose awaited, experts say

07 Jun 2019

Amgen’s (NASDAQ:AMGN) Phase I/II AMG510 efficacy data in non-small cell lung cancer (NSCLC) improves expert outlook on its KRAS G12C inhibition mechanism’s potential as a single agent, experts said. However, some expert caution remains due to currently poor colorectal cancer (CRC) data in the same trial, and overall low patient numbers for both indications.

Already a subscriber? Login to read the full article.

1 Start 2 Complete